EarliPoint Health Launches Project ALIGN to Advance Objective Measurement and Outcomes in Autism Care

Learn More →

Research Request Form

Tell us about your study and what you would like from EarliPoint. Submitting this form starts a review — it is not approval or a commitment.

This form allows qualified investigators to request support for independent, investigator-initiated research. EarliPoint does not solicit investigator-initiated research and does not guarantee that any request will be supported.

Submission of a request does not create any agreement or obligation by EarliPoint. If support is provided, the requestor shall serve as study sponsor and comply with all regulatory requirements, including IDE, IRB approval, informed consent, safety reporting, monitoring, and other obligations. EarliPoint does not assume and will not undertake such obligations. Requests are reviewed by an independent committee based on scientific merit and the research interest.

Support by EarliPoint is not offered as an inducement and is independent of any sales or commercial relationship. All support is limited to fair market value, and any transfer of value will be reported in accordance with applicable law. Questions should be directed to MedicalAffairs@EarliPointHealth.com.

Request A Demo

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder